Fluorescent form of AM 251. AM 251 conjugated with 5-carboxytetramethylrhodamine (5-TAMRA) that fluoresces at 543 nm excitation (590 nm emission). Displays GPR55 binding activity.
View more information regarding Tocrifluor T1117.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 974.97. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||10.26 mL||51.28 mL||102.57 mL|
|0.5 mM||2.05 mL||10.26 mL||20.51 mL|
|1 mM||1.03 mL||5.13 mL||10.26 mL|
|5 mM||0.21 mL||1.03 mL||2.05 mL|
References are publications that support the biological activity of the product.
Daly et al (2010) Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br.J.Pharmacol. 159 787 PMID: 20136833
Daly et al (2008) Visualisation of vascular cannabinoid receptors and their potential interaction with α1-adrenergic receptors. Vascular and Smooth Muscle Phys.Soc. Symposium
Sylantyev et al (2013) Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc.Natl.Acad.Sci.U.S.A. 110 5193 PMID: 23472002
Bruno et al (2014) Beyond radio-displacement techniques for identification of CB1 ligands: the first application of a fluorescence-quenching assay. Sci.Rep. 4 3757 PMID: 24441508
If you know of a relevant reference for Tocrifluor T1117, please let us know.
View Related Products by Target
Keywords: Tocrifluor T1117, Tocrifluor T1117 supplier, fluorescent, CB1, receptor, ligands, Fluorescent, Probes, cannabinoids, Receptors, cb1r, cb2r, Ligands, GPR55, 2540, Tocris Bioscience
3 Citations for Tocrifluor T1117
Citations are publications that use Tocris products. Selected citations for Tocrifluor T1117 include:
Stornaiuolo et al (2015) Endogenous vs Exogenous Allosteric Modulators in GPCRs: A dispute for shuttling CB1 among different membrane microenvironments. Sci Rep 5 15453 PMID: 26482099
Daly et al (2010) Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol 159 787 PMID: 20136833
Tortoriello et al (2013) Targeted lipidomics in Drosophila melanogaster identifies novel 2-monoacylglycerols and N-acyl amides. PLoS One 8 e67865 PMID: 23874457
Do you know of a great paper that uses Tocrifluor T1117 from Tocris? Please let us know.
Reviews for Tocrifluor T1117
There are currently no reviews for this product. Be the first to review Tocrifluor T1117 and earn rewards!
Have you used Tocrifluor T1117?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.